Metastatic prostate cancer men’s Attitude towards Treatment of the local Tumour and metastasis Evaluative Research (MATTER)
Systemic therapy has increased overall survival in men with hormone-sensitive metastatic prostate cancer. Novel local cytoreductive treatments and metastasis directed therapy are being evaluated, these can confer additional harm, but might improve survival. We aim to elicit men’s preferences for and willingness to accept trade-offs between potential improved survival and cytoreductive treatment risks using a discrete choice experiment.
HERU researchers involved in this research project: Verity Watson
External collaborators: Connor, M. and Ahmed, H. (Imperial College London)